Here are five quick facts:
1. Tenet’s short term standard deviation is valued at 14.46.
2. The company’s target price could reach $85 on the higher end.
3. On the lower end, analysts predict the target price could fall to $36.
4. The shares hold a recommendation consensus of “buy.”
5. In the last four weeks, the shares fell 9.2 percent.
More articles on surgery centers:
AmSurg shares fall 1.6% — 5 quick facts
Surgery Partners Q3 revenue up 214% — 10 key points
Tenet, Baylor Scott & White Health partner on 5 Texas hospitals — 5 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
